PTC Therapeutics Completes $550M 0% Convertible Notes Offering, Refinances Debt
PTCT sits 82% above its 52-week low of $43.175 on elevated volume (2.0× avg).
Summary
PTC Therapeutics has completed a $550 million offering of 0% convertible senior notes due 2031. This follows the announcement and pricing of the offering earlier this week. The notes feature favorable terms, including an initial conversion price of approximately $107.48 per share, representing a roughly 37% premium over the current stock price. A significant portion of the net proceeds, $328.8 million, will be used to repurchase $222.0 million of the company's 1.50% convertible notes due 2026, effectively refinancing existing debt and extending maturities.
At the time of this announcement, PTCT was trading at $78.42 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.6B. The 52-week trading range was $43.18 to $87.50. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.